(NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI ® ...

A father is appealing for donors as his teenage son faces a life-threatening blood disorder and needs a stem cell transplant within weeks to improve his chances of survival.

Across treatment classes, CH associated with increased therapy-related cytopenias, particularly neutropenia, and DNMT3A/TET2 ...

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in Nature ...

Crossbow announced it raised $77 million in a Series B financing that will advance the development of TCR-mimetic antibody ...

Juan Uribe is urgently seeking a stem cell donor for his 15-year-old son, Max, who has a rare blood disorder Max’s heritage ...

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic ...

Explore 6 Maryland biotech companies with recent funding, ready to bring their breakthrough technologies to the clinic.

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, ...

Rep. Mike Clampitt was diagnosed with cancer in 2025. The House speaker announced Clampitt's death on Wednesday.

After a strong start to the year, the value of biotech financings has tailed off a little, but March has seen a clutch of $50 ...